Share Email Print
cover

Proceedings Paper

Pharmacokinetic study of a systemically administered novel liposomal Temoporfin formulation in an animal tumor model
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Meso-tetra(hydroxyphenyl)chlorin (mTHPC)(international generic name Temoporfin) is a potent photosensitizer used for photodynamic therapy (PDT). In this study the pharmacokinetics of a systemically administered novel lipid formulation of Temoporfin in a murine tumor model has been investigated. Fluorescence spectroscopy measurements were performed at several time intervals following drug administration, yielding information on the Temoporfin concentration within excised internal organs as a function of time after injection. Both point-monitoring and imaging setups were used. The acquired fluorescence data were correlated to the concentration of Temoporfin obtained with High Performance Liquid Chromatography (HPLC). There was a significant correlation between the fluorescence methods and HPLC for most organs investigated. The pharmacokinetics of this new liposomal formulation of Temoporfin exhibited a rather flat temporal profile in the time interval 2-8 hours in this study.

Paper Details

Date Published: 27 February 2007
PDF: 8 pages
Proc. SPIE 6427, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XVI, 64270T (27 February 2007); doi: 10.1117/12.698932
Show Author Affiliations
Jenny Svensson, Lund Univ. (Sweden)
Ann Johansson, Lund Univ. (Sweden)
Niels Bendsoe, Lund Univ. Hospital (Sweden)
Susanna Gräfe, biolitec AG (Germany)
Tilmann Trebst, CeramOptec GmbH (Germany)
Stefan Andersson-Engels, Lund Univ. (Sweden)
Katarina Svanberg, Lund Univ. Hospital (Sweden)


Published in SPIE Proceedings Vol. 6427:
Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XVI
David Kessel, Editor(s)

© SPIE. Terms of Use
Back to Top